Innovative biomarkers for prostate cancer early diagnosis and progression

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 1, 2010, Pages 10-22

  You, Jingjing ^a,b   Cozzi, Paul ^a,c   Walsh, Bradley ^b   Willcox, Mark ^a,d   Kearsley, John ^a,c   Russell, Pamela ^a,e   Li, Yong ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Minomic International Ltd   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d BRIEN HOLDEN VISION INSTITUTE   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Biomarkers; Diagnosis; Prognosis; Prostate cancer; Proteomics; SELDI TOF MS

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; AUTOANTIBODY; BIOLOGICAL MARKER; EARLY PROSTATE CANCER ANTIGEN; KALLIKREIN; KALLIKREIN 2; NUCLEAR MATRIX PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; E26 ONCOGENE HOMOLOG GENE; E26 TRANSFORMING SEQUENCE VARIANT GENE 1; EARLY DIAGNOSIS; GENE; GENE FUSION; GLEASON SCORE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSMEMBRANE PROTEASE SERINE 2 GENE; TUMOR VOLUME; URINALYSIS;

EID: 83055179651     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.02.007     Document Type: Review

References (127)

1. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Tracey E, Chen S, Baker D, et al. Cancer in New South Wales, Incidence and Mortality Report 2004. Cancer Institute NSW: NSW Central Cancer Registry; 2006.
3. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-42.
4. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
5. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
6. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
7. Fowler FJ, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998;104:526-32.
8. Poteat HT, Chen P, Loughlin KR, et al. Appropriateness of prostatespecific antigen testing. Am J Clin Pathol 2000;113:421-8.
9. Merrill RM. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Prev Med 2001;33:646-52.
10. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology 2002;59:251-5.
11. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003;95:868-78.
12. Scales CD, Curtis LH, Norris RD, et al. Prostate specific antigen testing in men older than 75 years in the United States. J Urol 2006;176:511-4.
13. Lukes M, Urban M, ZaleskyM, et al. Prostate-specific antigen: current status. Folia Biol 2001;47:41-9. Praha.
14. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
15. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991;37:1618-25.
16. Antenor JAV, Han M, Roehl KA, et al. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004;172: 90-3.
17. Moul JW, Sun L, Hotaling JM, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007;177:499-503.
18. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen. Cancer 1997;80:1852-6.
19. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
20. Ahyai SA, Graefen M, Steuber T, et al. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level <= 4.0 ng per millilitre. Eur Urol 2008;53:750-7.
21. Stamey TA. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004;94:963-4 [see comment].
22. Tchetgen MBN, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin N Am 1997;24, 283-&.
23. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91.
24. Kim YJ, Han BK, Hong SK, et al. Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol 2007;14:1009-12.
25. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease-a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
26. Catalona WJ, Partin AW, Slawin KM, et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000;55:372-6.
27. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2-4 ng/ml. J Urol 2003;170:2181-5.
28. Sokoll LJ, Chan DW, Mikolajczyk SD, et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003;61:274-6.
29. Lein M, Semjonow A, Graefen M, et al. A multicenter clinical trial on the use of (-5-7) pro prostate specific antigen. J Urol 2005;174:2150-3.
30. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0-10.0 ng/ml. J Urol 2003;170:723-6.
31. Djavan B, Remzi M, Zlotta AR, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, freeto-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60:4-9.
32. Sozen S, Eskicorapci S, Kupelia B, et al. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. Eur Urol 2005;47: 302-7.
33. Mikolajczyk SD, Millar LS, Wang TJ, et al. BPSA, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55:41-5.
34. Canto EI, Singh H, Shariat SF, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004;63:905-10.
35. Patel DA, Presti JC, McNeal JE, et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005;23:6157-62.
36. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
37. Carter HB, Ferrucci L, Kettermann A, et al. Detection of lifethreatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7.
38. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191-6.
39. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53
40. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
41. Piironen T, Lovgren J, Karp M, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-41.
42. Grauer LS, Finlay JA, Mikolajczyk SD, et al. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998;19:407-11.
43. Partin AW, Catalona WJ, Finlay JA, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999;54:839-45.
44. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
45. SteuberT, Vickers AJ, Haese A, et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006;118:1234-40.
46. Steuber T, Vickers AJ, Serio AM, et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007;53:233-40.
47. Bussemakers MJG, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
48. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.
49. Hessels D, Gunnewiek J, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
50. Groskopf J, Aubin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
51. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5.
52. van Gils MP, Hessels D, van Hooj O, et al. The time resolved fluorescence-based PCA3 test on urinary sediments after extended digital rectal examination; a Dutch multicenter validation of the diagnostic performance. J Urol 2007;177:568-1568.
53. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-10.
54. Deras IL, Aubin SMJ, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
55. Dhir R, Vietmeier B, Arlotti J, et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004;171: 1419-23.
56. Uetsuki H, Tsunemori H, Taoka R, et al. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005;174:514-8.
57. Paul B, Dhir R, Landsittel D, et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005;65:4097-100.
58. Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004;96:834-43.
59. Bradley SV, Oravecz-Wilson KI, Bougeard G, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005;65:4126-33.
60. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-36.
61. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
62. Rochon YP, Horoszewicz JS, Boynton AL, et al. Western blot assay for prostate specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-23.
63. Murphy GP, Kenny GM, Ragde H, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998;51:89-97.
64. Douglas TH, Morgan TO, McLeod DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 1997;80:107-14.
65. Beckett ML, Cazares LH, Vlahou A, et al. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res 1999;5:4034-40.
66. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostatespecific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-33.
67. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostatespecific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-36.
68. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
69. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
70. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.
71. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007;17: 1033-6.
72. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.
73. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
74. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9.
75. Hermans KG, Bressers AA, van der Korput HA, et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008;68:3094-8.
76. Soller MJ, Elfving P, Lundgren R, Panagopols I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-9.
77. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101.
78. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusionassociated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
79. Nam RK, Sugar L, Wang ZH, et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-5.
80. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
81. Laxman B, Morris DS, Yu JJ, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
82. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.
83. Lexander H, Palmberg C, Hellman U, et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006;6:4370-80.
84. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008.
85. Ahn SM, Simpson RJ. Body fluid proteomics: prospects for biomarker discovery. Proteom Clin Appl 2007;1:1004-15.
86. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002;2:3-10.
87. Moritz RL, Ji H, Schutz F, et al. A proteome strategy for fractionating proteins and peptides using continuous free-flow electrophoresis coupled off-line to reversed-phase high-performance liquid chromatography. Anal Chem 2004;76:4811-24.
88. Norden AGW, Sharratt P, Cutillas PR, et al. Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine. Kidney Int 2004;66:1994-2003.
89. Grover PK, Resnick MI. High resolution two-dimensional electrophoretic analysis of urinary proteins of patients with prostatic cancer. Electrophoresis 1997;18:814-8.
90. Rehman I, Azzouzi AR, CattoJWF, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004;64:1238-43.
91. Qin S, Ferdinand AS, Richie JP, et al. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for lowabundance serum proteins. Proteomics 2005;5:3183-92.
92. Lam YW, Mobley JA, Evans JE, et al. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005;5:2927-38.
93. Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-85.
94. Ward DG, Suggett N, Cheng Y, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006;94:1898-905.
95. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005;41:40-7.
96. Le L, Chi K, Tyldesley S, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005;51:695-707.
97. Lehrer S, Roboz J, Ding H, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003;92:223-5.
98. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7 [see comment].
99. Hutchens T, Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-80.
100. Petricoin III EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8 [see comment].
101. Qu Y, Adam B-L, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43 [see comment].
102. Ornstein DK, RayfordW, FusaroVA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004;172:1302-5.
103. Kohli M, Siegel E, Bhattacharya S, et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark 2006;2:249-58.
104. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
105. Ekblad L, Baldetorp B, Ferno M, et al. In-source decay causes artifacts in SELDI-TOF MS spectra. J Proteome Res 2007;6:1609-14.
106. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDITOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
107. Lai Y, Adam B-l, Podolsky R, She J-X. A mixture model approach to the tests of concordance and discordance between two large-scale experiments with two-sample groups. Bioinformatics 2007;23:1243-50.
108. Petricoin EF, Ornstein DK, Liotta LA. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urology 2004;22:322-8.
109. M'Koma AE, Blum DL, Norris JL, et al. Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem Biophys Res Commun 2007;353:829-34.
110. Zhang WM, Finne P, Leinonen J, et al. Determination of prostatespecific antigen complexed to alpha(2)-macroclobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000;56:267-72.
111. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-8.
112. Le Page C, Koumakpayi IH, Alam-Fahmy M, et al. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006;94:1906-12.
113. Zehentner BK, Secrist H, Zhang XQ, et al. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol Diagn Ther 2006;10:397-403.
114. Shimada K, Matsuyoshi S, Nakamura M, et al. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005;206: 423-32.
115. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology 1998;51:141-5.
116. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. In: Circulating nucleic acids in plasma or serum Ii. New York: New York Acad. Sciences; 2001. p. 51-58.
117. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor gene expression and its relation to the estrogen-inducible HSP27 heat shock protein in hormone refractory prostate cancer. Prostate 2000;45:36-41.
118. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Maximum Ki-67 staining in prostate cancer provides independent prognosticinformation after radical prostatectomy. Anticancer Res 2001;21: 4071-6.
119. Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999;161:1238-43.
120. Huang CL, Brassil D, Rozzell M, et al. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as aserum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 1993;23:201-12.
121. Xu Y, Zhang T, Tang H, et al. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol 2005;92:326-30.
122. Said J. Biomarker discovery in urogenital cancer. Biomarkers 2005;10:S83-6.
123. Wang JH, Weng JS, Cai Y, et al. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate 2006;66:847-57.
124. Van Huizen I, Wu GJ, Moussa M, et al. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Clin Cancer Res 2005;11:7911-9.
125. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71:161-7.
126. Fuessel S, Sickert D, Meye A, et al. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 2003;23:221-8.
127. Henshall SM, Afar DEH, Hiller J, et al. Survival analysis of genomewide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.